Aim 1: Number of participants for whom "yes" is indicated for pain as assessed by the United Nations Istanbul Protocol (UNIP).
The UNIP results in a binary "yes" or "no" clinical pain diagnosis by the evaluator.
Aim 1: Number of participants for whom "yes" is indicated for pain as assessed by the United Nations Istanbul Protocol (UNIP) and the Brief Pain Inventory Short Form (BPISF).
As the UNIP results in a binary "yes" or "no" clinical pain diagnosis by the evaluator, the continuous BPISF will be converted into a binary "yes" or "no" for pain. Any participant who experiences interference as mild, moderate, or severe pain will be categorized as "yes" for pain; any participant who experiences pain as mild, moderate, or severe will be categorized as "yes" for pain. A score of 0 will be categorized as "no" for pain on the BPISF.
Aim 1: Number of participants for whom "yes" is indicated for pain as assessed by pain specialist evaluation.
The presence of pain detected by the pain specialist evaluation will be categorized as a binary "yes" or "no".
Aim 2: Themes emerging across qualitative interview transcripts.
A thematic coding scheme will be created following the main points of the interview guide. Reports will be generated for each code and narratives will be analyzed for common themes related to acceptability of pain treatments and the relationship between stress and chronic pain. We will utilize the data gained from this Aim to adapt the design of our proposed evidence-based somatic pain treatment model.
Aim 3: The recruitment as measured by the number of participants enrolled.
The investigators aim to recruit 20 participants.
Aim 3: The retention as measured by the number of participants who complete the follow-up appointment 6 months after their baseline appointment.
Aim 3: The adherence as measured by the number of participants who answer 1 or more Ecological Momentary Assessment (EMA) questions.
Participants are sent EMA questions each week to assess their levels of stress and pain, as well as their cardiovascular symptoms.
Aim 3: The adherence as measured by the number of participants who wear their Fitbit for 1 or more days.
Aim 3: Number of participants for whom "yes" is indicated for pain as assessed by the Brief Pain Inventory Short Form (BPISF).
The continuous BPISF will be converted into a binary "yes" or "no" for pain. Any participant who experiences mild, moderate, or severe pain or pain interference will be categorized as "yes" for pain; a score of 0 will be categorized as "no" for pain on the BPISF.
Aim 3: Number of participants for whom "yes" is indicated for pain as assessed by the Brief Pain Inventory Short Form (BPISF).
The continuous BPISF will be converted into a binary "yes" or "no" for pain. Any participant who experiences mild, moderate, or severe pain or pain interference will be categorized as "yes" for pain; a score of 0 will be categorized as "no" for pain on the BPISF.
Aim 3: The mean score for pain severity as assessed by the Brief Pain Inventory Short Form (BPISF).
Questions 3-6 on the BPISF assess mean pain severity score; these questions are scored on a scale of 0 to 10, with 0 indicating "no pain" and 10 indicating "pain as bad as you can imagine."
Aim 3: The mean score for pain severity as assessed by the Brief Pain Inventory Short Form (BPISF).
Questions 3-6 on the BPISF assess mean pain severity score; these questions are scored on a scale of 0 to 10, with 0 indicating "no pain" and 10 indicating "pain as bad as you can imagine."
Aim 3: The mean score for pain interference as assessed by the Brief Pain Inventory Short Form (BPISF).
Question 9 on the BPISF, comprised of 7 parts, assesses mean pain interference; these questions are scored on a scale of 0 to 10, with 0 indicating "does not interfere" and 10 indicating "completely interferes."
Aim 3: The mean score for pain interference as assessed by the Brief Pain Inventory Short Form (BPISF).
Question 9 on the BPISF, comprised of 7 parts, assesses mean pain interference; these questions are scored on a scale of 0 to 10, with 0 indicating "does not interfere" and 10 indicating "completely interferes."
Aim 3: Number of participants with positive scores on the Refugee Health Screener-15 (RHS-15).
Symptoms are scored from 0 to 4. A score of 0 indicates "not at all" and a score of 4 indicates "extremely." The survey also asks participants to rate their distress according to a distress thermometer; the thermometer scale ranges from 0 to 10, with 0 indicating "no distress" and 10 indicating "extreme distress." Screening is defined as positive with a total score greater than or equal to 12 on the first 14 items or a ranking greater than 5 on the distress thermometer.
Aim 3: Number of participants with positive scores on the Refugee Health Screener-15 (RHS-15).
Symptoms are scored from 0 to 4. A score of 0 indicates "not at all" and a score of 4 indicates "extremely." The survey also asks participants to rate their distress according to a distress thermometer; the thermometer scale ranges from 0 to 10, with 0 indicating "no distress" and 10 indicating "extreme distress." Screening is defined as positive with a total score greater than or equal to 12 on the first 14 items or a ranking greater than 5 on the distress thermometer.
Aim 3: Number of participants with positive scores on the Refugee Trauma History Checklist (RTHC).
The RTHC is comprised of binary "yes" and "no" questions. The RTHC is considered quantitatively positive if any item is marked as "yes."
Aim 3: Number of participants with positive scores on the Stress of Immigration - Short Form (SOIS-SF).
The SOIS-SF is considered positive if the participant answered a subscale score of more than 1 for any of the individual items in the survey. The subscale ranges from 1 to 5, with a score of 1 indicating "no stress" and a score of 5 indicating "severe stress."
Aim 3: Number of participants with positive scores on the Stress of Immigration - Short Form (SOIS-SF).
The SOIS-SF is considered positive if the individual answered a subscale score of more than 1 for any of the individual items in the survey. The subscale ranges from 1 to 5, with a score of 1 indicating "no stress" and a score of 5 indicating "severe stress."
Aim 3: The mean score on the Stress of Immigration - Short Form (SOIS-SF).
The SOIS-SF subscale ranges from 1 to 5, with a score of 1 indicating "no stress" and a score of 5 indicating "severe stress." The SOIS-SF is scored by averaging the scores of the 5-item survey. The mean of non-missing items results in a score of 1 to 5.
Aim 3: The mean score on the Stress of Immigration - Short Form (SOIS-SF).
The SOIS-SF subscale ranges from 1 to 5, with a score of 1 indicating "no stress" and a score of 5 indicating "severe stress." The SOIS-SF is scored by averaging the scores of the 5-item survey. The mean of non-missing items results in a score of 1 to 5.
Aim 3: Number of participants who say they would be willing to provide a saliva or hair sample to measure cortisol levels in a hypothetical future study.
Aim 3: Number of participants with positive scores on the Refugee Post Migration Stress Scale (RPMS).
The RPMS is considered positive if the individual answered a subscale score of more than 1 for any of the individual items in the survey. The subscale ranges from 1 to 5, with 1 indicating "never" and 5 indicating "very often." Items marked as a subscale score greater than 1 on the RPMS will be considered sources of stress.
Aim 3: Number of participants with positive scores on the Refugee Post Migration Stress Scale (RPMS).
The RPMS is considered positive if the individual answered a subscale score of more than 1 for any of the individual items in the survey. The subscale ranges from 1 to 5, with 1 indicating "never" and 5 indicating "very often." Items marked as a subscale score greater than 1 on the RPMS will be considered sources of stress.
Aim 3: Number of participants with positive scores on the Atherosclerotic Cardiovascular Disease Pooled Cohort Equation (ASCVD PCE).
Positive scores are indicated by ≥7.5% 10-year ASCVD risk (defined as first-occurrence nonfatal and fatal myocardial infarction (MI) and nonfatal and fatal stroke).
Aim 3: Number of participants with positive scores on the Atherosclerotic Cardiovascular Disease Pooled Cohort Equation (ASCVD PCE).
Positive scores are indicated by ≥7.5% 10-year ASCVD risk (defined as first-occurrence nonfatal and fatal myocardial infarction (MI) and nonfatal and fatal stroke).
Aim 3: Number of participants with positive scores on the World Health Organization Rose Angina Questionnaire (WHOAQ).
The WHOAQ is used to determine if a participant has experienced symptoms of a heart attack. The WHOAQ is positive if any symptoms are recorded.
Aim 3: Number of participants with positive scores on the World Health Organization Rose Angina Questionnaire (WHOAQ).
The WHOAQ is used to determine if a participant has experienced symptoms of a heart attack. The WHOAQ is positive if any symptoms are recorded.
Aim 3: Number of participants with positive scores on the Questionnaire Verifying Stroke Free Status (QVSFS).
The QVSFS is used to determine if a participant has experienced symptoms of a stroke. The QVSFS is positive if any questions are answered in the affirmative.
Aim 3: Number of participants with positive scores on the Questionnaire Verifying Stroke Free Status (QVSFS).
The QVSFS is used to determine if a participant has experienced symptoms of a stroke. The QVSFS is positive if any questions are answered in the affirmative.
Aim 3: Number of participants who have self-reports of Cardiovascular disease (CVD) symptoms and events.
Participants will be asked if they have experienced any of the following symptoms: anxiety, chest pain, depression, dizziness, dyspnea, fatigue.
Aim 3: Number of participants who have self-reports of Cardiovascular disease (CVD) symptoms and events.
Participants will be asked if they have experienced any of the following symptoms: anxiety, chest pain, depression, dizziness, dyspnea, fatigue.
Aim 3: Number of participants who have pain, stress, or CVD symptoms, as signalled by continuous biometric data.
Biometric data including continuous heart rate, actigraphy, sleep, and derived physiological parameters (e.g., resting heart rate and estimated energy expenditure) will be collected using the wrist-worn wearable device.